Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist. It inhibits platelet aggregation.
## Primary Indications
* Prevention of thrombotic events (e.g., myocardial infarction, stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months. After 12 months, consider continuing 90 mg twice daily or switching to a lower dose (e.g., 60 mg twice daily) based on individual risk assessment for stent thrombosis versus bleeding.
* **Post-MI (at least 1 year after ACS, or in patients with prior MI without ACS):** 60 mg orally twice daily.
## Pediatric Dosing
* Ticagrelor is not approved for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required for mild to severe renal impairment.
* **Hepatic Impairment:** No dose adjustment required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to limited data.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack or stroke.
* Known hypersensitivity to ticagrelor or any of its excipients.
* Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) is generally not recommended.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including fatal and severe), bradycardia, ventricular pauses.
* **Serious:** Major bleeding, minor bleeding, clinically significant bleeding.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid concomitant use with strong CYP3A4 inhibitors. Use caution with other CYP3A4 substrates, as ticagrelor may increase their concentrations.
* **CYP3A4 Inducers:** Potent inducers of CYP3A4 (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure and efficacy.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Consider risks and benefits of coadministration.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea.
* Monitor heart rate for bradycardia.
## Clinical Pearls
* Ticagrelor should be initiated as soon as possible in patients with ACS, regardless of whether they are undergoing percutaneous coronary intervention.
* When switching from or to another P2Y12 inhibitor, ticagrelor should be administered without interruption of therapy.
* The 90 mg twice daily dose is typically used for 12 months in ACS patients. After this period, consider reducing to 60 mg twice daily based on individual risk.
* Aspirin is recommended as maintenance therapy in combination with ticagrelor for all patients with ACS. The maintenance dose of aspirin should be guided by local protocols and individual patient assessment, generally not exceeding 100 mg daily.
***
*Disclaimer: This information is intended for healthcare professionals and should not replace clinical judgment. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.*
